Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$287K Sell
2,233
-5
-0.2% -$585 0.09% 102
2026
Q1
$269K Sell
2,238
-5
-0.2% -$577 0.09% 100
2025
Q4
$236K Buy
+2,243
New +$211K 0.08% 91
2025
Q2
Sell
-2,325
Closed -$209K 97
2025
Q1
$209K Sell
2,325
-42
-2% -$3.92K 0.08% 85
2024
Q4
$235K Sell
2,367
-342
-13% -$35.3K 0.09% 83
2024
Q3
$308K Buy
2,709
+46
+2% +$5.46K 0.13% 71
2024
Q2
$330K Sell
2,663
-199
-7% -$25.6K 0.14% 61
2024
Q1
$378K Buy
2,862
+202
+8% +$24.9K 0.17% 53
2023
Q4
$290K Buy
+2,660
New +$276K 0.14% 62

Other funds holding MRK

Skyline Advisors's MRK Position: Q2 2026 in Review

Skyline Advisors reduced its Merck (MRK) stake by 0.22% in Q2 2026, selling an estimated $585 and leaving 2,233 shares worth $287K. The position accounts for 0.09% of the portfolio, ranked #102.

Skyline Advisors first reported a position in MRK in Q4 2023 and has held it in 9 quarters since. The position peaked at $378K in Q1 2024. 1,737 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Skyline Advisors held 2,233 shares of Merck worth $287K as of Q2 2026.
  • Skyline Advisors sold 5 Merck shares in Q2 2026, an estimated $585.
  • Merck made up 0.09% of Skyline Advisors's portfolio in Q2 2026, its #102 holding.
  • Skyline Advisors first reported a position in Merck in Q4 2023 and has held it in 9 quarters since.
  • Skyline Advisors's Merck position peaked at $378K in Q1 2024.
  • 1,737 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Skyline Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.